BACKGROUND: To improve the prediction of prostate cancer (PCA) risk and pathological type of PCA by non-invasive approaches before performing prostatic biopsy are the current challenges for the management of PCA. The aim of this present study was evaluate the clinical validity of prostate cancer associated 3 (PCA3) gene in the prediction of PCA and the correlations between the PCA3 level and prognostic factors. METHODS: A total of 207 patients with suspected prostate cancer in Ningbo No. 2 hospital between June 2012 and July 2014 were enrolled in this study. All patients included underwent prostate biopsy under the direction of digital rectal examination (DRE) and were divided into PCA group and no evidence of malignancy (NEM) group according to the pathological diagnosis. We analyzed the association between PCA3 score and indicators of prognosis (Gleason score, percentage of positive cores and clinical stage) by multivariate analysis. RESULTS: The levels of total prostate-specific antigen (t-PSA), prostate health index (PHI) and PCA3 score in patients with PCA were significantly higher than those in NEM group (P<0.05). In PCA group, PHI value and t-PSA were both factors significantly correlated with high Gleason score and clinical stage (P<0.05). A high PCA3 score in urine was significantly correlated with a high Gleason score, % positive cores and an advanced clinical stage (P<0.05). CONCLUSION: PCA3 score might be one of useful diagnostic tools for determining suitable therapeutic programs for PCa and predicting the prognosis.
BACKGROUND: To improve the prediction of prostate cancer (PCA) risk and pathological type of PCA by non-invasive approaches before performing prostatic biopsy are the current challenges for the management of PCA. The aim of this present study was evaluate the clinical validity of prostate cancer associated 3 (PCA3) gene in the prediction of PCA and the correlations between the PCA3 level and prognostic factors. METHODS: A total of 207 patients with suspected prostate cancer in Ningbo No. 2 hospital between June 2012 and July 2014 were enrolled in this study. All patients included underwent prostate biopsy under the direction of digital rectal examination (DRE) and were divided into PCA group and no evidence of malignancy (NEM) group according to the pathological diagnosis. We analyzed the association between PCA3 score and indicators of prognosis (Gleason score, percentage of positive cores and clinical stage) by multivariate analysis. RESULTS: The levels of total prostate-specific antigen (t-PSA), prostate health index (PHI) and PCA3 score in patients with PCA were significantly higher than those in NEM group (P<0.05). In PCA group, PHI value and t-PSA were both factors significantly correlated with high Gleason score and clinical stage (P<0.05). A high PCA3 score in urine was significantly correlated with a high Gleason score, % positive cores and an advanced clinical stage (P<0.05). CONCLUSION:PCA3 score might be one of useful diagnostic tools for determining suitable therapeutic programs for PCa and predicting the prognosis.
Authors: Monique J Roobol; Fritz H Schröder; E David Crawford; Stephen J Freedland; A Oliver Sartor; Neil Fleshner; Gerald L Andriole Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet Journal: Clin Chem Date: 2003-01 Impact factor: 8.327
Authors: Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera Journal: Oncotarget Date: 2018-04-17
Authors: Carla Solé; Ibai Goicoechea; Alai Goñi; Maike Schramm; María Armesto; María Arestin; Lorea Manterola; Maitena Tellaetxe; Aitor Alberdi; Leonor Nogueira; Mathieu Roumiguie; Jose Ignacio López; Juan Pablo Sanz Jaka; Ander Urruticoechea; Itziar Vergara; Ana Loizaga-Iriarte; Miguel Unda; Arkaitz Carracedo; Bernard Malavaud; Charles H Lawrie Journal: Cancers (Basel) Date: 2020-02-22 Impact factor: 6.639